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Abstract

33

Study question: Are early signs of metabolic disorder in late adolescence associated with features of

34

impaired testicular function many years before the majority are seeking parenthood?

35

Summary answer: Adolescents with features of metabolic disorder, as manifest by ultrasound

36

evidence of non-alcoholic fatty liver (NAFL) at 17 years or systemic markers of inflammation, and/or

37

insulin resistance measured by homeostasis model of insulin resistance (HOMA-IR) at 20 years of

38

age, have reduced testicular volume, total sperm output, serum testosterone (T) and inhibin B (inhB)

39

concentrations and a higher serum follicle stimulating hormone concentration (FSH), at 20 years of

40

age, in comparison to their peers without metabolic disorder.

41

What is known already: Controversial evidence suggests a recent decline in sperm production

42

potentially linked to environmental influences, but its cause remains unclear. The concomitant

43

increases in obesity and diabetes suggests that lifestyle factors may contribute to this decline in

44

testicular function. Although obesity has been associated with adverse testicular function in some

45

studies, it remains unclear whether poor testicular function reflects, or causes, poor metabolic health.

46

If metabolic disorder were present in adolescence, prior to the onset of obesity, this may suggest that

47

metabolic disorder may lead to impaired testicular function

48

Study design, size, duration: The Western Australian Pregnancy Cohort (Raine) Study is a

49

longitudinal study of children born in 1989-1991 who have undergone detailed physical assessments

50

since birth (1454 male infants born). The purpose of this current sub-study was to perform a testicular

51

assessment at 20 years of age (913 were contactable).

52

At 17 years of age 490 underwent a hepatic ultrasound examination, serum cytokine assessment

53

(n=520) and a metabolic assessment (n=544). A further metabolic assessment was performed at 20

54

years (n=608). Testicular assessment was performed on 20 year participants who consented to

55

inclusion; 609 had reproductive hormones measured, 404 underwent a testicular ultrasound and 365

56

produced a semen sample.

57

Participants/materials, setting, methods: Testicular volume was estimated by ultrasonography, and

58

semen analysis performed by WHO methods. Serum was analysed to determine concentrations of
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59

luteinising hormone (LH), FSH, inhB by immunoassays and T by liquid chromatography-mass

60

spectrometry (LC-MS).

61

At 17 years of age a liver ultrasound examination was performed to determine the presence of NAFL,

62

and serum analysed for the following cytokines; interleukin-18 (IL18), soluble tumour necrosis factor

63

receptor 1 & 2 (sTNFR1, sTNFR2) concentrations.

64

At 17 and 20 years of age fasting blood samples were analysed for serum liver enzymes, insulin,

65

glucose, triglycerides (TG), total cholesterol, high density lipoprotein (HDL) and low density lipoprotein

66

(LDL) cholesterol, high sensitivity (hs) CRP, and uric acid. HOMA was calculated and insulin

67

resistance (IR) was defined by a HOMA >4, anthropometric data was collected and dual energy X-ray

68

absorptiometry (DEXA) measurement was performed for lean and total fat mass. As at this young age

69

the prevalence of metabolic syndrome was expected to be low, a two-step cluster analysis was used

70

using waist circumference, TGs, insulin, and systolic blood pressure to derive a distinct high-risk

71

group with features consistent with the metabolic syndrome.

72

Main results and the role of chance: Men who at age 17 years were at elevated cardiometabolic

73

risk had lower concentrations of T (medians: 4.0ng/ml vs 4.9ng/ml) and inhB (medians: 193.2pg/ml vs

74

221.9pg/ml) (p<0.001 for both) compared to those within the low risk metabolic cluster. Furthermore,

75

men with ultrasound evidence of NAFLD detected at 17 years (n=45, 9.8%) had reduced total sperm

76

output (medians: 68.0 million vs 126.00 million, p=0.044), T (4.0ng/ml vs 4.7ng/ml, p=0.005) and inhB

77

(209.1pg/ml vs 218.4pg/ml, p=0.032) concentrations at 20 years compared to men without NAFLD..

78

Men with higher concentrations of sTNFR1, at 17 years of age, had a lower sperm output and seminal

79

volume, and serum concentrations of inhB, with an increase in LH and FSH at 20 years of age (all

80

p<0.05 after adjustment for age, body mass index [BMI], abstinence and a history of cryptorchidism

81

and varicocele, cigarette smoking, alcohol and drug use). Similarly, serum T was lower in men with a

82

higher fasting serum insulin, hsCRP, HOMA and total fat mass, and higher in men with higher fasting

83

HDL, iron at 20 years of age (all p<0.05). Multivariable regression analysis, adjusting for age and BMI

84

at 20 years, cryptorchidism and presence of a varicocele examined the associations between NAFLD

85

(at 17 years), and HOMA-IR >4 and metabolic cluster (at 20 years) with reproductive hormone

86

concentrations at age 20 years, demonstrated that men in the high-risk metabolic cluster at 20 years

4

87

had a lower serum T and inhB (both p=0.012), and HOMA-IR >4 was associated with a lower serum T

88

(p=0.002), .

89

Limitations, reasons for caution: This study is limited by the sample size and multiple comparisons,

90

and causality cannot be proven from an observational study. Due to a three year interval between

91

some metabolic assessments and assessment of testicular function, we cannot exclude an

92

introduction of a bias into the study, as some of the participants and their testicular function will not

93

have been fully mature at the 17 year assessment.

94

Wider implications of the findings: Irrespective of a proven causation, our study findings are

95

important in that a significant minority of the men, prior to seeking parenthood, presented co-existent

96

features of metabolic disorder and signs of testicular impairment. Of particular note is that the

97

presence of NAFLD at 17 years of age, although only present in a minority of men, was associated

98

with an almost 50% reduction in sperm output at 20 years of age, and that the presence of IR at 20

99

years was associated with a 20% reduction in testicular volume.

100
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117

Introduction

118

There is an on-going debate in reproductive medicine as to whether there has been a general decline

119

in sperm production in recent times, potentially linked to environmental influences (1-3). The parallel

120

increase in the rates of lifestyle related disorders, such as obesity and diabetes (4), raises the

121

possibility that lifestyle factors may contribute to any potential decline in sperm production. In

122

populations of men seeking fertility treatment, obesity has been associated with adverse testicular

123

function; such as reduced testicular volume, seminal volume, sperm output, sperm motility, serum

124

testosterone concentration and sperm DNA damage (5-9), although this has been challenged (10).

125
126

The metabolic syndrome is a cluster of adverse cardiovascular features including central obesity,

127

atherogenic dyslipidemia, insulin resistance, a prothrombotic state, elevated blood pressure and

128

increased circulating proinflammatory markers. Some evidence exists for an association between the

129

metabolic syndrome and impaired testicular function in sub-fertile men (9, 11). However, causality is

130

unclear whether these disorders have a common origin in early life (12), or whether impaired

131

testicular function may induce or result from the metabolic disorder.

132
133

With the increase in the prevalence of features of the metabolic syndrome in adolescent populations

134

(13), many will have ultrasound evidence of a fatty liver (14). Non-alcoholic fatty liver disease

135

(NAFLD) is the most prevalent chronic liver disorder, affecting almost 1 in 5 adolescents (15), and is a

136

recognized

137

Hyperinsulinemia, or the presence of a fatty liver (17), is associated with a reduction in hepatic

138

synthesis of sex hormone binding globulin (SHBG), increasing the metabolic clearance of

139

testosterone.

antecedent

of

progressive

liver

disease

and

cardiometabolic

disorder

(16).

140
141

The metabolic syndrome is associated with a low grade inflammatory state, with increased C-reactive

142

protein (CRP) and production of inflammatory cytokines, such as, Interleukin- 6 (IL-6), tumour

143

necrosis factor -α (TNF-α), and their receptors 1 and 2 (TNFR1 and TNFR2), and the production of

144

oxygen free radicals, all of which may impair sperm and testicular function (18, 19). We therefore

145

proposed that impaired testicular function may reflect or cause poor metabolic health.

146
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147

Our study was driven by the question; whether or not in a young adult population, representative of

148

the Western Australian population (20), early signs of metabolic disorder are associated with a profile

149

of impaired testicular function, many years before the majority of men seek paternity. Hence our aim

150

was to relate antecedent and concurrent markers of adverse cardiometabolic health, in adolescence

151

and early adulthood, to markers of testicular function within men at 20 years of age from the Western

152

Australian Pregnancy Cohort (Raine) Study.

153
154

Materials and Methods

155

The Raine study

156

The Raine Study (www.rainestudy.org.au) was designed to measure the relationships between early

157

life events and subsequent health and behaviour. The study recruited 2900 women around 18 weeks

158

of gestation in 1989-91 (20, 21). 2868 children (including 1454 boys) born to 2804 mothers were

159

retained to form the Raine Study cohort, and were studied every 2-3 years into early adulthood,

160

including detailed cardiometabolic assessment at 17 and 20 years of age, and 423 men underwent

161

testicular assessment by ultrasound and / or semen examinations (20, 22). Ethical approval was

162

obtained from the University of Western Australia Human Research Ethics Committee, and all

163

participants provided informed written consent for all aspects of the study.

164
165

Testicular function assessment

166

Clinical and testicular function assessment at 20 years of age

167

All male cohort members were invited to attend follow-up, which involved questionnaires, collection of

168

anthropometric data (n=687), and collection of blood for analysis of serum testosterone, luteinizing

169

hormone (LH), FSH and inhB concentrations (n=609). A testicular ultrasound examination was

170

performed (n=404), and a semen sample (n=365) analysed at Fertility Specialists of Western

171

Australia, as previously reported (22). Semen samples were analysed as per WHO semen manual

172

guidelines (23) including sperm concentrations (million per ml), total sperm output (million per

173

ejaculate), motility (%A grade + %B grade) and morphology. The sperm chromatin structural assay

174

(SCSA) was performed as described (24) with slight modifications. The DNA fragmentation index

175

represents the percentage of sperm within the sample with fragmented or damaged DNA. Serum inhB

176

concentration was measured by Gen II ELISA (Beckman Coulter Inc. Brea, CA); LH and FSH were
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177

measured by ELISA (IBL International, Hamburg, Germany), and testosterone was measured by

178

liquid chromatography-tandem mass spectrometry (LC-MS/MS) as described (25) (for further details

179

refer to supplementary methods [sM]). Testicular ultrasonography was performed as described (22),

180

and the volume of each testis calculated (26). Varicocele was defined as present when the maximal

181

venous diameter was over 3mm, and increased with the Valsalva manoeuver (27).

182
183

Metabolic assessments

184

1. Metabolic assessment at 17 years of age

185

a. Hepatic ultrasound

186

The methods of hepatic ultrasound examinations conducted among 587 cohort members at age 17

187

years for diagnosing NAFL have been reported previously, and the data was used in this study (sM)]

188

(14).

189

b. Cytokine assessment

190

The serum from 520 cohort members was stored at -80 C and was analysed for the following

191

cytokines; interleukin-18 (IL18) by ELISA, soluble tumor necrosis factor receptor 1 & 2 (sTNFR1,

192

sTNFR2). Plasma IL-18 was quantitated with a commercially available ELISA method. Plasma

193

sTNFR1 and sTNFR2 were quantified using cytometric Bead Array. Individual cytokine concentrations

194

were determined using FCAP Array software (BD Biosciences) (sM).

195
196

c. Cardiometabolic assessment

197

Data from previous publication (13) was extracted for the fasting blood samples from 549 cohort

198

members which were analysed at the PathWest Laboratory at Royal Perth Hospital for serum liver

199

enzymes, insulin, glucose, triglycerides (TG), total cholesterol, HDL and LDL cholesterol, hsCRP, and

200

uric acid, as previously described (13, 29), excluding serum hsCRP concentrations >10mg/l (13, 29).

201

Glucose, insulin, total cholesterol and triglycerides were measured by automated analysers (sM).

202

HOMA was calculated by fasting insulin (microunits per milliliter) × fasting glucose (millimoles per

203

liter)]/22.5, and insulin resistance (IR) was defined by a HOMA >4 (30). Resting blood pressure (BP)

204

readings were taken (sM). The cardiometabolic data was used to derive a ‘high risk metabolic cluster’

205

phenotyped previously in this cohort (13), and described below.

206
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207

2. Cardiometabolic assessment at 20 years of age

208

Fasting blood samples from 620 cohort members at 20 years of age were analysed according to the

209

same protocol for the 17 year cardiometabolic assessment. To assess body fat distribution DEXA

210

measurement was performed (31, 32).

211
212
213

Statistical Considerations

214

Derivation of metabolic cluster at 20 years of age

215

The two most frequently used definitions of the metabolic syndrome in adulthood are the National

216

Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood

217

cholesterol in adults (NCEP ATP-III) (33), and the International Diabetes Federation definition (IDF)

218

(34), which differ significantly on the components of their definition (see details in sM). Hence, as

219

there is no universally accepted definition, and it was expected that at this young age the prevalence

220

of metabolic syndrome would be low, an alternative approach, a two-step cluster analysis was used

221

(13, 35, 36). This is an effective tool used to define groups accounting for variables for where there is

222

strong evidence of clustering. Within a single cluster, the subjects are relatively homogeneous,

223

sharing similar traits and being dissimilar to subjects in other clusters. The technique uses a scalable

224

cluster analysis algorithm (37), designed specifically to handle large data sets and has been used

225

previously within this cohort (13, 35, 36). It preselects subjects into sub-clusters before further

226

grouping into the desired number of clusters with use of log-likelihood distance. The cluster groups

227

were formed with use of; waist circumference, TGs, insulin, and systolic BP measured at 20 years of

228

age to derive distinct high-risk group with features consistent with the metabolic syndrome. This

229

approach was used previously to identify those Raine study participants within a high risk metabolic

230

cluster at 17 years of age (13).

231
232

Data analysis

233

Continuous data were summarized using medians and inter-quartile ranges (IQR), reported as Q1–

234

Q3, when following a non-Gaussian distribution. Categorical data were summarized using frequency

235

distributions. Multivariable linear regression analysis was used to examine associations between

236

metabolic parameters and reproductive outcomes or hormone concentrations. Covariate adjustments
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237

included abstinence, history of cryptorchidism, varicoceles and BMI. Regression results were

238

summarized using standardised coefficients (β) and their 95% confidence intervals (CI). Effects of the

239

metabolic parameters on outcomes were presented without (β1) and with (β2) adjustment for BMI.

240

Supplementary analyses adjusting for waist circumference instead of BMI were performed with

241

analogous results (data not shown). Reproductive outcomes had a non-Gaussian distribution, and

242

were transformed to normality either via logarithmic or power transformations determined using the

243

Box-Cox analysis.

244
245

Differences in reproductive parameters and hormone concentrations across low and high risk

246

metabolic clusters, HOMA-IR, NAFLD, insulin and hsCRP were investigated univariately using Mann-

247

Whitney test for two groups. When appropriate univariable analyses were supplemented with

248

multivariable analyses to control for confounders age and BMI at 20 years, cryptorchidism and

249

presence of a varicocele. All hypothesis tests were two-sided and p-values of <0.05 were considered

250

statistically significant. No adjustments for multiple hypothesis testing were made in this exploratory

251

study (38, 39). SPSS (version 22.0, IBM SPSS) statistical software was used for data analysis.

252
253

Results

254

Demographics

255

Of 913 male cohort members who were contactable, 365 (40%) provided a semen sample and

256

represented 48% of the men who attended any of the assessments at 20 years of age and 404

257

underwent a testicular ultrasound and 609 had serum available for reproductive hormone assessment

258

(Table 1). Most (587) had undergone a liver ultrasound at 17 years of age and/or a fasting metabolic

259

assessment (544), and up to 608 had undergone some aspect of metabolic assessment at age 20

260

years of age (Table 2). Participants who took part in the testicular assessment (semen sample and/or

261

testicular ultrasound) were similar clinically to those that declined participation (Table 2). There was

262

no difference between the participants and the non-participants with respect to markers of socio-

263

economic status (data not shown sM). The prevalence of metabolic syndrome among males within

264

the participants was 4.1% by the NCEP-ATPIII definition (40) and 5.4% using the IDF definition (34).

265
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266

Associations between markers of metabolic disorder and testicular parameters

267
268

Metabolic indices at 17 years.

269

Multivariable linear regression analysis adjusting for current age, abstinence, a history of

270

cryptorchidism, presence of a varicocele, and BMI revealed the association of semen parameters with

271

markers of systemic inflammation at 17 years of age: total sperm output was reduced in men at 20

272

years of age who had a higher serum IL18 (p=0.025), or sTNFR1 (p=0.036) and their sperm

273

concentration was negatively associated with their serum IL18 concentration (p=0.020) measured at

274

17 years (Table 3A). In addition higher sTNFR1 was negatively associated with inhibin B (p=0.011),

275

and positively associated with serum LH and FSH (p=0.015, and p=0.001 respectively) three years

276

later (Table 4). When adjustment was performed for waist circumference instead of BMI the results

277

were analogous (data not shown). We have previously shown that alcohol use, cigarette smoking and

278

recreational drug use in this cohort had no influence on markers of testicular function (22), and that

279

testicular volume was positively associated with height, and total soft and lean body mass(12)

280
281

Associations between metabolic cluster analysis at 17 years and subsequent testicular function at 20

282

years of age

283

At 17 years of age 70 of 439 participants (15.9%) who would subsequently undergo the male

284

reproductive assessment were clustered within the high metabolic risk group.

285
286

In an unadjusted analysis of the reproductive hormones of men within the high risk metabolic cluster

287

at 17 years of age, had median T and inhB concentrations significantly lower (p<0.001 for both), in

288

comparison to the men within the low risk metabolic cluster (Table 5).

289
290

Metabolic indices at 20 years.

291

After adjustment for age, abstinence, a history of cryptorchidism, varicocele and BMI; diastolic blood

292

pressure and serum insulin at 20 years of age were negatively associated with testicular volume

293

(p=0.028 and p=0.004 respectively), although diastolic blood pressure was positively associated with

294

total sperm output (p=0.020) and seminal volume (p=0.014). ALT and GGT were positively associated

295

with sperm morphology (p=0.008 and p=0.028 respectively) (Table 3A).
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296
297

Associations between markers of metabolic disorder at 20 years of age and sex hormones

298

Multivariable regression analyses with adjustment for history of cryptorchidism and presence of a

299

varicocele shown that serum total testosterone (TT) was reduced in men with a higher fasting serum;

300

triglycerides, insulin, hsCRP, ferritin, ALT, HOMA score, and DEXA indices of fat when measured

301

concurrently at 20 years of age (Table 4) (all p<0.05). Serum TT was positively associated with serum

302

HDL cholesterol, iron and transferrin saturation (all p<0.05). After simultaneous adjustment for BMI

303

(and waist circumference-data not shown) positive associations with serum HDL, iron, transferrin

304

saturation and lean mass remained and a negative association with hsCRP and serum insulin

305

remained (all p<0.05).

306
307

Associations between metabolic cluster analysis at 20 years of age and testicular function

308

The number of men in the high risk metabolic cluster at 20 years of age, those insulin resistant as

309

measured by the HOMA score and with NAFL, varied within the analyses due to the varying number

310

of participants who took part in the various sub-studies (Table 1).

311
312

In an unadjusted analysis of the men within the high risk metabolic cluster at 20 years of age, their

313

median T and inhB concentrations were lower than men within the low risk metabolic cluster (Table

314

5, supplementary figures [sF] 1a and 1b).

315
316

Associations between HOMA as a proxy for IR at 20 years of age and testicular function

317

IR (as defined by a HOMA>4) was present in 24 out of 616 men (3.9%) at 20 years of age. In an

318

unadjusted analysis, in comparison to those participants who were not IR, their median testicular

319

volume was smaller, and median T and inhB concentrations were lower, and their median serum FSH

320

concentration was higher (Table 6, sF2a-d). Furthermore the 51 men, out of 609 (8.4%), who had a

321

fasting serum insulin greater than 10 μU/ml (91st centile), at 20 years of age had lower median serum

322

T and inhB concentrations, and their FSH concentration was greater (supplementary table [sT]1,

323

sF3a-c).

324
325

Associations between presence of NAFLD at 17 years of age and subsequent testicular function
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326

Ultrasound evidence of NAFLD was present in 44 men, out of 458 (9.6%) who subsequently

327

underwent some assessment of testicular function. Compared to those participants without NAFLD,

328

there were reductions in their; median total sperm output, serum T and inhB concentrations (sT2 and

329

sF4a-c).

330
331

Associations between serum hsCRP either; above or below, the 75% percentile at 20 years of age

332

and testicular function

333

Men whose serum hsCRP was greater than the 75% centile (1.62mg/l) at 20 years of age (after

334

exclusion of concentrations >10mg/l), in comparison to those below, had a reduction in their median

335

seminal volume, serum T, LH and FSH concentrations (sT3, sF5a-d).

336
337

Multivariable analysis

338

Multivariable analysis demonstrated that being in the high risk metabolic cluster at 20 years of age

339

was associated with a lower serum testosterone and inhB, and HOMA-IR >4 was associated with a

340

lower serum testosterone concentration at 20 years (sT4).

341
342

Discussion

343

The findings of this observational study of adult men at 20 years of age, demonstrated that despite

344

the majority of men being of normal weight, a small minority already displayed features of metabolic

345

disturbance which are associated with adverse cardiovascular outcomes at a much older age. Men

346

with features of the metabolic syndrome, or who were IR at 20 years of age, or had ultrasound

347

evidence of NAFLD at 17 years of age, displayed a picture consistent with a degree of primary

348

hypogonadism as they had reductions in testicular volume, sperm output, and serum testosterone and

349

inhB, with a reciprocal increase in serum FSH at 20 years of age. All of these variables are well

350

established as adverse markers of reproductive potential (2, 22). Furthermore in considering potential

351

mechanisms for the observed finding it is possible there are contrasting influences of metabolic

352

disorder as; higher concentrations of the inflammatory markers sTNFR1 (and IL18 to a lesser

353

degree), when measured at 17 years were associated with subsequent reductions in sperm output,

354

seminal volume, sperm concentration, inhB, with reciprocal rises in LH and FSH, at 20 years of age,

355

suggesting a direct gonadotoxic effect of adolescent inflammation on subsequent testicular function,
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356

and in contrast higher concentrations of hsCRP at 20 years of age had a potential central negative

357

influence on serum FSH secretion (and LH to a lesser degree), inducing a central hypogonadal state

358

with reductions in serum testosterone and seminal volume, however without a concomitant reduction

359

inhB and testicular volume, these could be chance associations.

360
361

One can speculate that if their cardiometabolic picture deteriorates over time, their testicular function

362

might further deteriorate, leading to an adverse effect on their reproductive potential. Conversely if

363

their metabolic picture improves, this may have a positive impact on their reproductive potential,

364

although. it is interesting to note that already at 20 years of age, irrespective of BMI, the markers of

365

cardiometabolic disorder; a higher fasting serum insulin, triglycerides, hsCRP, HOMA score and

366

DEXA fat mass were negatively associated with the testicular hormones; serum testosterone and

367

inhB, concentrations, while a higher total lean mass, serum HDL cholesterol and iron stores were

368

positively associated with these hormones. These findings offer a potential link between metabolic

369

and reproductive health, in that these adverse metabolic features recorded at 17 and 20 years of age

370

may predispose a man to later impaired testicular function, irrespective of adiposity. Although the

371

direction of causality will require further investigation, as it is established that a low circulating

372

testosterone is associated with cardiometabolic disorder (41-43). However, data from one prospective

373

study suggests that a low serum testosterone may be a risk marker for the development of

374

cardiometabolic disorder, rather than a causative risk factor (44). Due to a three year interval between

375

some metabolic assessments and assessment of testicular function, we cannot exclude an

376

introduction of a bias into the study, as some of the participants and their testicular function will not

377

have been fully mature at the 17 year assessment, and it is known that pubertal maturation can have

378

a moderating impact on obesity associated inflammation (45). Irrespective of a proven causation, our

379

study findings are important in that a significant minority of the men, prior to seeking parenthood,

380

presented with some features of metabolic disorder and signs of testicular impairment.

381
382

These study findings warrant further study in other cohorts. Of particular note is that the presence of

383

NAFLD at aged 17 years of age, although only present in a minority of men, was associated with an

384

almost 50% reduction in sperm output at 20 years of age, and that the presence of IR at 20 years was

15

385

associated with; a 20% reduction in testicular volume, a 30% reduction in serum testosterone, and a

386

20% reduction in serum inhB concentrations.

387
388

Conclusion

389

This study has demonstrated an association of adverse cardiometabolic features with impaired

390

testicular function at 20 years of age. Furthermore, it is notable that, despite the majority of the young

391

men having apparently normal metabolic function, a significant minority were already showing some

392

features of the metabolic syndrome.

393
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Supplementary Methods on line
Hepatic ultrasound examination
Ultrasonographers experienced in hepatic ultrasound performed the ultrasound examinations, as
described (14), according to the protocol described by Hamaguchi (28), which provides 92%
sensitivity and 100% specificity for the histological diagnosis of fatty liver (14). Boys with sonographic
fatty liver and a self-reported weekly alcohol intake of less than 140g over the previous 12 months
were classified as having NAFLD. Testing for hepatitis B or C virus infections was not performed due
to low notification rates for these infections in local teenagers during the study period (14).

Sex hormone measurement; Serum inhibin B concentrations were measured in duplicate by Inhibin B
Gen II ELISA from Beckman Coulter Inc. (Brea, CA), which had a limit of detection of 2.6 pg/ml.
Luteinising hormone (LH), follicular stimulating hormone (FSH) levels were determined in duplicate
using ELISA kits from IBL International, Hamburg, Germany. The limit of detection of the LH assay
was 0.4 IU/L (calibrated against WHO IRP 80/552), while for FSH assay it was 0.2 IU/L (calibrated
against NIBSC 92/510). The intra-assay precision (CV) of the ELISAs ranged from 8-11% based on
the mean values for low and high value quality control samples from n=16-17 assays.

Measurement of serum inflammatory markers;
Cytokine assessment
The serum from 520 cohort members was stored at -80 C and was analysed for the following
cytokines; interleukin-18 (IL18) by ELISA (Medical Biological Laboratories, Nagoya, Japan), soluble
tumor necrosis factor receptor 1 & 2 (sTNFR1, sTNFR2). Plasma IL-18 was quantitated with a
commercially available ELISA method (Medical Biological Laboratories, Nagoya, Japan). Plasma
sTNFR1 and sTNFR2 were quantified using cytometric Bead Array (CBA) Flex sets (BD PharMingen,
San Diego, CA) on the BD FACSArrayTM bioanalyser (BD Biosciences, San Jose, California, USA).
Procedures followed the manufacturer’s recommendations. Individual cytokine concentrations were
determined using FCAP Array software (BD Biosciences). The IL-18: Intra- and inter-assay
coefficients of variation (CV) were 5.6% and 7.6%, respectively, with a sensitivity: 12.5 pg/Ml.

c. Cardiometabolic assessment

Fasting blood samples from 454 cohort members were analysed at the PathWest Laboratory at Royal
Perth Hospital for serum liver enzymes, insulin, glucose, triglycerides (TG), total cholesterol, high
density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol, high sensitivity (hs) CRP, and
uric acid, as previously described (14, 31), excluding serum hsCRP concentrations >10mg/l (14, 31).
Glucose was measured by an automated Technicon Axon analyser (Bayer Diagnostics, Sydney,
Australia) using a hexokinase method. Insulin was measured by automated radioimmunoassay
(Tosoh, Tokyo, Japan). Total cholesterol and triglycerides were determined enzymatically on the
Cobas MIRA analyzer (Roche Diagnostics) with reagents from Trace Scientific (Melbourne, Australia)
(supplementary methods).

The intra-assay CV was 0.87% for total cholesterol, 1.92% for triglycerides, 1.04% for glucose,
1.78%. The intra- and inter-assay CV for insulin was 2.5%, sensitivity: 0.9 ng/Ml. For leptin the intra
and inter-assay CV were 3.3% and 5.4%, respectively, with a sensitivity of 7.8 pg/mL.

Resting blood pressure (BP) readings were taken using an oscillometric sphygmomanometer
(DINAMAP vital signs monitor 8100, DINAMAP XL vital signs monitor, or DINAMAP ProCare 100),
Soma Technology Bloomfiled, Connecticut) with the subject seated. The monitor was set to
automatically record readings every 2 minutes and the mean of the second and third readings was
calculated.

Sociodemographic assessment
Family income when children were aged 14 years was obtained by questionnaire from the primary
caregiver, and the highest maternal education was obtained by questionnaire when children were
aged 8 years (20).

The commonest definitions of metabolic syndrome
The NCEP ATP III guidelines state that the metabolic syndrome may be diagnosed when a person
has three or more of five components: central obesity (waist circumference), an elevated TG level, a
reduced HDL-cholesterol level, an elevated BP or an elevated fasting glucose concentration (35). The

IDF definition requires a person to have central obesity plus any two of four additional factors: a
raised TG level: a reduced HDL-cholesterol: a raised BP or a raised fasting plasma glucose (known
type 2 diabetes) (36).

Supplementary tables on-line

Supplementary Table 1. Comparison of testicular volume, semen parameters and serum hormones by serum insulin
concentration above or below 10μu/ml, all assessments made at 20 years of age. Data are represented as Median (IQR,
R).
Variables of interest
Testicular volume (ml)
Semen parameters
Volume (ml)
Total sperm output (M)

NHigh
28

Insulin ≥ 10 μu/ml
14.8 (12.5-16.6, 10.0-23.8)

NNormal
345

Insulin < 10 μu/ml
15.1 (12.7-17.3, 7.6-28.4)

p-value
0.646

22
22

2.9 (1.6-4.1, 0.8-7.2)
134.4 (44.3-239.0, 0-436)

317
317

0.799
0.578

Sperm concentration (M/ml)
SCSA (%)
Morphology (N, %)
Motility (a + b, %)
Serum hormones
Testosterone (ng/mL)
LH (IU/l)
FSH (IU/l)
InhB (pg/ml)

22
21
21
21

45.5 (19.1-84.5, 0-160)
2.9 (1.6-5.0, 1.1-10.8)
6.0 (3.5-9.0, 2-17)
54.0 (44.5-69.0, 19-79)

317
311
307
314

2.8 (2.0-3.7, 0.1-11.0)
110.5 (51.6-206.8, 0.0927.5)
45.0 (22.5-70.5, 0-220)
3.1 (1.8-5.2, 0.2-30.0)
5 (3-7, 0-18)
58 (43-67, 1-88)

51
51
51
51

3.6 (2.9-4.8, 1.1-7.1)
9.9 (7.5-12.9, 5.6-18.8)
5.2 (3.3-7.3, 1.1-25.8)
174.0 (136.7-222.3, 28.9-389.3)

556
557
557
558

4.7 (3.7-5.9, 1.3-10.3)
10.5 (8.3-13.1, 2.3-28.4)
4.2 (2.9-6.0, 0.6-39.5)
218.6 (176.8-268.9, 4.5543.9)

<0.001
0.287
0.018
<0.001

0.795
0.658
0.159
0.907

Supplementary Table 2. Comparison of testicular volume, semen parameters and serum testicular hormones and
gonadotrophins, assessed at 20 years of age, by ultrasound evidence of NAFLD, at 17 years of age. Data is represented
as Median (IQR, R).
Outcome
Testicular volume (ml)
Sperm parameters
Semen volume (ml)
Total sperm output (M)

NNAFLD
28

NAFLD
15.0 (12.6-17.2, 10.5-23.2)

NNormal
270

No NAFLD
14.8 (12.6-17.3, 7.6-28.4)

p-value
0.821

25
25

2.5 (1.6-3.3, 0.7-6.2)
68.0 (23.2-170.9, 0.0-551.8)

255
255

0.161
0.044

Sperm concentration (M/ml)
SCSA (%)
Sperm morphology (N, %)
Sperm motility (a + b, %)
Serum hormone concentrations
Testosterone (ng/ml)
LH (IU/l)
FSH (IU/l)
InhB (pg/ml)

25
24
24
24

26 (15-69, 0-113)
4.0 (1.8-5.9, 0.7-13.6)
5 (3-7, 1-17)
56.5 (370-67.8, 6-82)

255
249
246
252

2.8 (1.9-3.8, 0.3-11.0)
126.0 (55.8-213.0, 0.0927.5)
47 (25-71, 0-220)
3.0 (1.9-5.4, 0.2-30.0)
5 (3-7, 0-15)
58 (43-67, 1-88)

44
44
44
44

4.0 (3.2-5.0, 1.1-7.2)
8.8 (7.3-12.8, 5.4-18.9)
3.6 (2.7-5.6, 1.2-14.3)
209.1 (145.85-253.2, 48.7389.3)

391
393
393
393

4.7 (3.6-5.9, 1.3-9.9)
10.7 (8.6-13.4, 2.3-28.4)
4.3 (3.1-6.3, 0.6-39.5)
218.4 (179.7-270.5, 4.5543.9)

0.005
0.054
0.428
0.032

0.060
0.428
0.979
0.591

Supplementary Table 3. Comparison of testicular volume, semen parameters and serum hormones by serum hsCRP
concentration by 75% percentile, all assessments made at 20 years of age. Data are represented as Median (IQR, R).
Individuals with hsCRP>10 were excluded.
Variables of interest
Testicular volume (ml)
Semen parameters
Volume (ml)
Total sperm output (M)
Sperm concentration (M/ml)
SCSA (%)
Morphology (N, %)
Motility (a + b, %)
Serum hormones
Testosterone (ng/ml)
LH (IU/l)
FSH (IU/l)
InhB (pg/ml)

NHigh
60

hsCRP ≥ 1.615 mg/l
15.4 (12.2-17.1, 8.9-23.5)

NNormal
299

hsCRP < 1.615 mg/l
14.9 (12.9-17.2, 7.6-28.4)

p-value
0.955

53
53
53
51
51
52

2.5 (1.6-3.1, 0.7-6.8)
84.8 (49.1-166.9, 0.0-639.2)
35 (23-63, 0-180)
2.9 (1.7-5.1, 0.7-10.8)
5 (4-8, 2-13)
52.5 (40.3-65.8, 10.0-86.0)

275
275
275
271
267
273

3.0 (2.0-3.8, 0.1-11.0)
118.4 (50.4-214.6, 0.0-927.5)
47.0 (21.5-74.0, 0-220)
3.1 (1.9-5.4, 0.2-30.0)
5 (3-7, 0-18)
58 (43-67, 1-88)

0.043
0.127
0.209
0.606
0.239
0.276

126
126
126
126

4.0 (3.2-5.2, 1.1-8.1)
9.5 (7.7-12.3, 4.3-19.5)
3.9 (2.7-5.2, 0.6-14.3)
216.3 (156.0-260.2, 48.7-419.1)

456
458
458
458

4.8 (3.8-6.0, 1.7-9.9)
10.7 (8.6-13.2, 2.3-28.4)
4.4 (3.0-6.4, 0.6-39.5)
216.2 (174.2-269.7, 4.5-543.9)

<0.001
0.008
0.024
0.201

Supplementary Table 4 Multivariate regression analysis to derive which metabolic risk factor individually remains
significant, after adjustments for age and BMI at 20 years, cryptorchidism, and presence of a varicocele, on the
reproductive hormones measured at 20 years of age. Three separate models, with either; HOMA at 20 years, NAFLD or
metabolic cluster at 20 years were examined for each outcome. Model summaries include univariable and multivariable
(adjusted) regression coefficients with their corresponding 95% confidence intervals (95% CI) and p-values; together with
R2 obtained in univariable models and an increase in R2 (denoted R2 change) in adjusted models are shown. P-value for
R2 change is reported to indicate whether the simultaneous adjustment for other characteristics improves prediction of
outcomes. All measurements other than assessment for presence of NAFL (assessed at 17 years of age), were taken at
20 years of age.

Outcome
(Total n=260)
Testosterone
HOMA-IR
NAFLD
Metabolic
cluster
FSH
HOMA-IR
NAFLD
Metabolic
cluster
Inhibin B
HOMA-IR
NAFLD
Metabolic
cluster

Univariable

Multivariable

β (95% CI)

p-value

R2

p-value

Adjusted β (95% CI)

p-value

R2 change

p-value
for

-0.54 (-0.85, -0.24)
-0.24 (-0.48, 0.009)
-0.43 (-0.62, -0.25)

<0.001
0.004
<0.001

0.036
0.014
0.060

<0.001
0.059
<0.001

-0.48 (-0.78,-0.18)
-0.12 (-0.37, 0.14)
-0.28 (-0.50, -0.06)

0.002
0.364
0.012

0.063
0.050
0.026

<0.001
0.010
0.056

0.01 (-0.001, 0.034)
0.002 (-0.01, 0.01)
0.003 (-0.01, 0.01)

0.061
0.667
0.547

0.004
0.000
0.002

0.263
0.998
0.547

0.013 (-0.007, 0.034)
0.02 (-0.02, 0.01)
0.01 (-0.01, 0.02)

0.202
0.842
0.546

0.012
0.013
0.015

0.375
0.487
0.275

-10.5 (-22.9, -6.15)
-3.0 (-12.7, 6.7)
-11.3 (-22.0, -2.5)

0.097
0.545
<0.001

0.008
0.001
0.042

0.097
0.545
<0.001

-8.7 (-20.8, 3.44)
1.1 (-8.9, 11.1)
-11.3 (-22.0, -2.5)

0.160
0.829
0.012

0.074
0.075
0.050

<0.001
0.001
0.001

NAFL = Non-alcoholic fatty liver diagnosed on ultrasound
HOMA = homeostasis model assessment insulin

1
Table 1. Flow of study participants. Total number of participants with measurements available are shown as
(n=maximum number of participants) and the maximal number of participants for each outcome out of testicular
volume, semen sample and blood sample assessment according to measurements taken during the various followups listed. The presence of non-alcoholic fatty liver (NAFL) was derived from a previous study Ayonirynde et al
(14) and the data identifying individuals within or without the high cardiometabolic risk cluster, derived using cluster
analysis in a previous study Huang et al (13)
Pregnant women enrolled in the Raine study
Live births
Male infants
Female infants
Male participants who had at least one of
testicular ultrasound, semen or blood
samples (n=648)
Participants who underwent 16/17 ±
20/21 follow-up

16/17 year follow up
Serum cytokines assessment
Liver ultrasound for NAFL
presence(14)
Serum available for full metabolic
assessment (13)
20/21 year follow up
Contactable
Participated
Anthropometric examination
Blood pressure measured
Serum available for biochemistry
Serum available for full metabolic
assessment
Serum for HOMA calculation
DEXA scan performed

2900
2868
1454
1414

Testicular volume
assessment
performed
(n=404)
Total
Testicular
participants
volume
measurements
underwent
available
assessment
(n)
(n)

Semen sample
provided
(n=365)

(n=520)
(n=587)

319
298

290
280

478
437

(n=544)

289

264

439

(n=913)
(n=705)
(n=687)
(n=693)
(n=620)
(n=608)

391
374
367

360
340
337

603
609
599

(n=618)
(n=634)

373
362

339
333

609
557

Semen sample
parameters
available
(n)

NAFL = Non-alcoholic fatty liver diagnosed on ultrasound
HOMA = homeostasis model assessment insulin (fasting insulin [μu/ml] × fasting glucose [mM]/22.5).
DEXA = Dual energy X-ray absorptiometry

N

Serum available for
reproductive
hormones
(n=609)
Serum sample
available for
gonadotrophins and
testosterone
(n)

2
Table 2. Participant characteristics at 20 years of age – comparison between those who participated in at least one aspect
of the testicular assessment and those who did not. Unless otherwise specified, data were collected at 20 years of age.
Male participants
Male non-participants
n=648
n=57
N
Median (IQR, R) or N (%)
N
Median (IQR, R) or N (%)
Age at 17 year follow-up
487 17.0 (16.9-17.1, 16.3-18.0)
33
17.0 (16.9-17.1, 16.7-17.3)
Age at 20 year follow-up
648 19.9 (19.7-20.3, 19.3-22.1)
57
19.9 (19.6-20.5, 19.4-21.7)
Anthropometric
Height (cm)
632 180 (170-180, 162-199)
55
180 (180-190, 156-198)
Weight (kg)
632 75.9 (68.3-86.2, 52.2-137.5)
55
75.8 (69.0-86.1, 50.2-176.5)
BMI (kg/m2)
632 23.6 (21.4-26.3, 16.7-48.9)
55
23.9 (21.5-25.5, 18.0-42.9)
under 25
405 (64.1%)
39 (70.9%)
25 - 30
155 (24.5%)
10 (18.2%)
30 plus
72 (11.4%)
6 (10.9%)
Waist circumference (cm)
632 80.5 (75.1-87.5, 43.8-145.5)
55
80.8 (74.3-88.3, 63.5-131.5)
Adiposity (DEXA)
Total fat mass (g)
586 14935 (10519-2431, 341348
15349 (10604-20633, 6583105957)
50244)
Total lean mass (g)
586 56702 (52052-61561, 3374748
57479 (51526-63403, 3867983318)
89622)
Soft tissue percentagea
586 21 (16-28, 6-63)
48
20 (16-28, 10-46)
Total fat percentageb
586 20 (15-27, 5-61)
48
19 (15-27, 10-45)
Biochemistry
Fasting glucose (mmol/l)
616 5.0 (4.8-5.3, 3.1-8.2)
2
Triglycerides (mmol/l)
616 1.0 (0.7-1.3, 0.3-17.8)
2
HDL cholesterol (mmol/l)
616 1.2 (1.0-1.4, 0.6-2.6)
2
LDL cholesterol (mmol/l)
616 2.4 (1.9-2.8, 0.2-5.3)
2
Iron (umol/L)
617 16.1 (12.8-20.5, 3.0-40.7)
2
Transferrin (umol/l)
617 31.6 (29.0-34.0, 21.2-46.5)
2
Transferrin saturation (%)
617 26.2 (20.7-32.8, 4.7-84.1)
2
Ferritin (ug/l)
392 87.8 (61.9-127.2, 6.3-326.9)
2
Insulin (μu/ml)
616 2.0 (2.0-4.7, 2.0-64.3)
2
High sensitivity CRP (mg/l) c
591 0.6 (0.3-1.4, 0.1-9.8)
2
ALT (u/l)
616 30 (22-42, 10-372)
2
GGT (u/l)
616 17 (14-23, 7-83)
2
AST (u/l)
616 25 (22-31, 11-199)
2
Adiponectin (mg/l)
616 7.6 (5.1-10.3, 0.6-34.6)
2
616 3.3 (1.7-7.0, 0-162.1)
2
Leptin (μg/l)
HOMA
616 0.5 (0.4-1.1, 0.3-16.3)
2
HOMA>4c
616 24 (3.9%)
2
0
Metabolic clusters
High risk at 20yrs
606 76 (12.5%)
2
0
High risk at 17 yrs
439 70 (15.9%)
15
2 (13.3%)
Blood pressure
Systolic (mm/Hg)
636 122 (114-132, 90-160)
57
123 (112-131, 91-152)
Diastolic (mm/Hg)
636 65 (59-71, 46-96)
57
64 (60-69, 47-90)
Serum reproductive hormones
Testosterone (ng/mL)
607 4.6 (3.6-5.8, 1.1-10.3)
LH (iu/l)
608 10.5 (8.3-13.0, 2.3-28.4)
FSH (iu/l)
608 4.3 (3.0-6.2, 0.6-39.5)
InhB (pg/ml)
609 216.4 (170.4-266.4, 4.5-543.9)
Cytokines(at 17 yrs)
IL18 (pg/ml)
496 288.4 (231.2-373.9, 0-3122)
23
263.6 (236.4-363.1, 153-1109)
sTNFR1 (pg/ml)
497 364.4 (286.1-462.8, 11-3549)
23
362.2 (293.7-420.4, 189-668)
sTNFR2 (pg/ml)
497 3180.4 (2636.3-3930.8, 2423
3222.3 (2588.0-4057.2, 19309150)
5737)
Hepatic ultrasound (at 17 yrs)
NAFLD
459 45 (9.8%)
31
4 (12.9%)
Tobacco and alcohol use
Smoking^
494 78 (15.8%)
38
34 (15.8%)
Alcohol consumption^
Nil
492 85 (17.3%)
37
6 (16.2%)
Moderate
249 (50.6%)
11 (29.7%)
Binge
158 (32.1%)
58 (28.2%)

Total soft tissue fat percentage = fat mass x 100 / (fat mass + lean mass), b Total fat percentage = fat mass x 100 / (fat mass +
lean mass + bone mineral content), c hsCRP>10 has been excluded. ^Smoking has 154 missing in the participants and 19 in the
non-participants group. Alcohol consumption has 156 missing in the participants and 20 missing in the non-participants group.
a

Replaced with Table 3 and Table 3A

p-value
0.598
0.786
0.550
0.884
0.887
0.543
0.995
0.843
0.790
0.771
0.740

0.792
0.609

0.802
0.874
0.853
0.757
1.000
0.923

3
Replaced with new Table 4
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Table 3A. Associations between reproductive and metabolic parameters at 20/21 years of age summarised using standardized beta coefficients and their 95% confidence intervals (CI). All
analyses were adjusted for age at 20 years of age, history of cryptorchidism and varicocele (β1), coefficients also adjusted for BMI at 20 years of age are shown as (β2Semen parameters were
also adjusted for abstinence period. Unless otherwise specified, data were collected at 20 years of age.

Biochemistry

Testis volume
β1 (95% CI)
β2 (95% CI)

Semen volume
β1 (95% CI)
β2 (95% CI)

Sperm output
β1 (95% CI)
β2 (95% CI)

Semen concentration
β1 (95% CI)
β2 (95% CI)

Glucose

-0.043 (-0.143, 0.057)

-0.057 (-0.157, 0.044)

0.066 (-0.034, 0.166)

0.078 (-0.023, 0.179)

0.071 (-0.026, 0.168)

0.085 (-0.013, 0.182)

0.057 (-0.045, 0.159)

0.065 (-0.038, 0.168)

Triglycerides

-0.047 (-0.147, 0.053)

-0.070 (-0.173, 0.032)

-0.044 (-0.144, 0.057)

-0.029 (-0.132, 0.074)

-0.044 (-0.141, 0.053)

-0.027 (-0.127, 0.004)

-0.012 (-0.114, 0.090)

-0.003 (-0.108, 0.102)

HDL cholesterol

-0.027 (-0.126, 0.073)

-0.002 (-0.106, 0.103)

0.030 (-0.070, 0.130)

0.010 (-0.095, 0.115)

0.027 (-0.070, 0.124)

0.003 (-0.098, 0.105)

-0.010 (-0.092, 0.111)

-0.003 (-0.110, 0.103)

LDL cholesterol

0.028 (-0.073, 0.128)

0.009 (-0.094, 0.112)

-0.023 (-0.123, 0.078)

-0.007 (-0.111, 0.096)

-0.001 (-0.099, 0.096)

0.018 (-0.082, 0.118)

0.015 (-0.087, 0.118)

0.026 (-0.079, 0.131)

Iron

-0.019 (-0.119, 0.081)

-0.017 (-0.117, 0.083)

0.092 (-0.008, 0.192)

0.090 (-0.010, 0.191)

-0.012 (-0.010, 0.086)

-0.014 (-0.111, 0.084)

-0.059 (-0.161, 0.043)

-0.060 (-0.162, 0.042)

Transferrin

0.081 (-0.019, 0.180)

0.072 (-0.028, 0.172)

0.020 (-0.080, 0.120)

0.029 (-0.072, 0.129)

-0.067 (-0.167, 0.033)

-0.057 (-0.153, 0.040)

-0.075 (-0.177, 0.026)

-0.071 (-0.174, 0.031)

Transferrin saturation %

-0.046 (-0.147, 0.054)

-0.041 (-0.141, 0.059)

0.076 (-0.025, 0.177)

0.072 (-0.029, 0.173)

-0.001 (-0.098, 0.097)

-0.006 (-0.103, 0.092)

-0.039 (-0.141, 0.064)

-0.042 (-0.145, 0.061)

Ferritin

-0.040 (-0.141, 0.060)

-0.057 (-0.159, 0.045)

-0.049 (-0.150, 0.053)

-0.037 (-0.140, 0.066)

-0.060 (-0.158, 0.037)

-0.047 (-0.147, 0.052)

-0.031 (-0.133, 0.072)

-0.024 (-0.128, 0.081)

Insulin

-0.116 (-0.215, -0.016)

-0.153 (-0.256, -0.049)

-0.036 (-0.137, 0.065)

-0.017 (-0.122, 0.088)

-0.013 (-0.111, 0.084)

0.011 (-0.091, 0.113)

0.001 (-0.101, 0.104)

0.015 (-0.092, 0.122)

hsCRP†

-0.003 (-0.105, 0.099)

-0.029 (-0.135, 0.077)

-0.113 (-0.216, -0.010)

-0.101 (-0.208, 0.007)

-0.065 (-0.164, 0.035)

-0.046 (-0.149, 0.057)

-0.046 (-0.150, 0.058)

-0.037 (-0.146, 0.071)

ALT

-0.034 (-0.135, 0.066)

-0.061 (-0.165, 0.043)

-0.106 (-0.207, -0.006)

-0.093 (-0.202, 0.016)

-0.008 (-0.105, 0.090)

0.015 (-0.086, 0.117)

0.024 (-0.078, 0.127)

0.039 (-0.068, 0.145)

AST

-0.010 (-0.112, 0.092)

-0.041 (-0.149, 0.066)

-0.031 (-0.133, 0.072)

0.009 (-0.117, 0.098)

-0.045 (-0.143, 0.054)

-0.021 (-0.125, 0.082)

-0.031 (-0.135, 0.073)

-0.019 (-0.128, 0.090)

GGT

0.003 (-0.097, 0.103)

-0.003 (-0.103, 0.097)

-0.021 (-0.121, 0.080)

-0.015 (-0.116, 0.085)

-0.017 (-0.115, 0.080)

-0.011 (-0.108, 0.086)

-0.018 (-0.119, 0.084)

-0.014 (-0.117, 0.088)

Systolic

0.005 (-0.097, 0.103)

-0.028 (-0.132, 0.076)

0.094 (-0.003, 0.191)

0.135 (0.032, 0.238)

0.006 (-0.089, 0.100)

0.038 (-0.062, 0.139)

-0.039 (-0.138, 0.060)

-0.028 (-0.134, 0.078)

Diastolic

-0.109 (-0.207, -0.011)

-0.124 (-0.223, -0.025)

0.112 (0.014, 0.209)

0.124 (0.026, 0.223)

0.100 (0.005, 0.194)

0.114 (0.018, 0.209)

0.049 (-0.050, 0.149)

0.057 (-0.044, 0.157)

Cytokines at 16/17 yrs
years
IL18

0.022 (-0.088, 0.132)

0.026 (-0.084, 0.135)

0.003 (-0.107, 0.112)

-0.001 (-0.110, 0.109)

-0.116 (-0.222, -0.011)

-0.120 (-0.225, -0.015)

-0.129 (-0.239, -0.019)

-0.131 (-0.242, -0.011)

sTNFR1

-0.089 (-0.197, 0.020)

-0.094 (-0.203, 0.014)

-0.123 (-0.232, -0.015)

-0.118 (-0.228, -0.009)

-0.119 (-0.224, -0.013)

-0.113 (-0.219, -0.007)

-0.045 (-0.157, 0.066)

-0.043 (-0.155, 0.068)

sTNFR2

-0.009 (-0.118, 0.101)

-0.013 (-0.122, 0.096)

-0.084 (-0.193, 0.026)

-0.081 (-0.190, 0.029)

-0.079 (-0.185, 0.027)

-0.076 (-0.181, 0.030)

-0.065 (-0.177, 0.048)

-0.063 (-0.176, 0.049)

Total fat %

-0.018 (-0.122, 0.086)

-0.129 (-0.266, 0.007)

-0.086 (-0.189, 0.018)

-0.068 (-0.205, 0.070)

-0.096 (-0.199, 0.007)

-0.073 (-0.206, 0.059)

-0.045 (-0.150, 0.060)

-0.029 (-0.169, 0.111)

Soft tissue fat %

-0.035 (-0.139, 0.069)

-0.137 (-0.266, -0.008)

-0.084 (-0.187, 0.020)

-0.064 (-0.201, 0.073)

-0.095 (-0.195, 0.005)

-0.072 (-0.205, 0.060)

-0.046 (-0.151, 0.060)

-0.030 (-0.170, 0.109)

Total fat mass

0.046 (-0.058, 0.149)

-0.041 (-0.196, 0.115)

-0.071 (-0.174, 0.032)

-0.040 (-0.196, 0.116)

-0.102 (-0.202, -0.003)

-0.094 (-0.245, 0.057)

-0.065 (-0.170, 0.039)

-0.076 (-0.234, 0.083)

Total lean mass

0.299 (0.202, 0.397)

0.366 (0.249, 0.433) *

0.096 (-0.005, 0.198)

0.196 (0.076, 0.317)

0.004 (-0.094, 0.103)

0.071 (-0.047, 0.189)

-0.055 (-0.159, 0.048)

-0.046 (-0.170, 0.079)

-0.121 (-0.220, -0.021)

-0.157 (-0.260, -0.054)

-0.032 (-0.133, 0.069)

-0.013 (-0.118, 0.092)

-0.004 (-0.101, 0.094)

0.021 (-0.081, 0.122)

-0.011 (-0.091, 0.114)

0.026 (-0.081, 0.132)

Blood pressure

DEXA

Metabolic syndrome
HOMA
†

hsCRP>10 are excluded (n=10); effects significant at 0.05 level are shown in bold. *p<0.001
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Table 3B. (Table 3 continued) Associations between semen parameters and metabolic parameters at 20/21 years of age summarised using standardized beta coefficients and their 95%
confidence intervals (CI). All analyses were adjusted for age at 20 years of age, history of cryptorchidism and varicocele (β1), coefficients also adjusted for BMI at 20 years of age are shown as
(β2Semen parameters were also adjusted for abstinence period. Unless otherwise specified, data were collected at 20 years of age.

Biochemistry

β1 (95% CI)

SCSA

β2 (95% CI)

β1 (95% CI)

Morphology

β2 (95% CI)

β1 (95% CI)

Motility

β2 (95% CI)

Glucose

0.011 (-0.094, 0.116)

0.006 (-0.100, 0.112)

0.042 (-0.064, 0.149)

0.038 (-0.070, 0.146)

0.080 (-0.023, 0.184)

0.081 (-0.024, 0.185)

Triglycerides

-0.065 (-0.170, 0.040)

-0.078 (-0.186, 0.030)

-0.018 (-0.124, 0.089)

-0.027 (-0.137, 0.083)

0.051 (-0.053, 0.154)

0.052 (-0.055, 0.159)

HDL cholesterol

-0.081 (-0.185, 0.024)

-0.077 (-0.186, 0.033)

0.031 (-0.076, 0.138)

0.045 (-0.067, 0.157)

-0.046 (-0.150, 0.057)

-0.048 (-0.157, 0.060)

LDL cholesterol

0.010 (-0.096, 0.115)

0.002 (-0.107, 0.110)

-0.039 (-0.147, 0.068)

-0.049 (-0.159, 0.061)

0.117 (0.014, 0.221)

0.122 (0.016, 0.228)

Iron

-0.011 (-0.117, 0.095)

-0.010 (-0.116, 0.095)

-0.054 (-0.162, 0.053)

-0.054 (-0.161, 0.054)

0.004 (-0.101, 0.108)

0.004 (-0.101, 0.108)

Transferrin

-0.026 (-0.130, 0.079)

-0.030 (-0.136, 0.075)

-0.011 (-0.117, 0.096)

-0.015 (-0.122, 0.093)

-0.055 (-0.159, 0.048)

-0.057(-0.161, 0.047)

Transferrin saturation %

-0.012 (-0.094, 0.118)

0.014 (-0.092, 0.121)

-0.055 (-0.162, 0.052)

-0.053 (-0.161, 0.055)

0.020 (-0.084, 0.125)

0.021 (-0.084, 0.126)

Ferritin

0.047 (-0.059, 0.153)

0.041 (-0.066, 0.149)

-0.065 (-0.173, 0.042)

-0.073 (-0.183, 0.036)

0.065 (-0.040, 0.169)

0.065 (-0.041, 0.172)

Insulin

-0.006 (-0.112, 0.100)

-0.018 (-0.129, 0.092)

0.048 (-0.059, 0.156)

0.042 (-0.070, 0.155)

0.037 (-0.067, 0.141)

0.038 (-0.071, 0.147)

hsCRP†

-0.027 (-0.134, 0.081)

-0.040 (-0.152, 0.072)

0.053 (-0.056, 0.162)

0.048 (-0.066, 0.161)

-0.008 (-0.115, 0.098)

-0.011 (-0.122, 0.100)

ALT

0.006 (-0.100, 0.111)

0.005 (-0.115, 0.105)

0.149 (0.043, 0.255)

0.151 (0.040, 0.262)

0.012 (-0.093, 0.116)

0.010 (-0.098, 0.119)

AST

-0.030 (-0.137, 0.077)

-0.045 (-0.158, 0.067)

0.069 (-0.043, 0.181)

0.067 (-0.051, 0.185)

-0.010 (-0.116, 0.096)

-0.014 (-0.125, 0.098)

GGT

-0.044 (-0.149, 0.061)

-0.047 (-0.152, 0.058)

0.122 (0.016, 0.228)

0.120 (0.013, 0.226)

0.024 (-0.079, 0.128)

0.024 (-0.080, 0.128)

Systolic

-0.001 (-0.103, 0.101)

-0.016 (-0.125, 0.093)

-0.002 (-0.106, 0.102)

-0.015 (-0.126, 0.096)

0.024 (-0.077, 0.124)

0.024 (-0.084, 0.132)

Diastolic

-0.007 (-0.110, 0.096)

-0.012 (-0.117, 0.092)

-0.049 (-0.154, 0.056)

-0.055 (-0.166, 0.057)

0.059 (-0.043, 0.160)

0.059 (-0.044, 0.161)

IL18

0.017 (-0.098, 0.132)

0.019 (-0.097, 0.134)

-0.009 (-0.126, 0.108)

-0.007 (-0.124, 0.110)

0.0003 (-0.113, 0.114)

0.001 (-0.113, 0.115)

sTNFR1

-0.030 (-0.145, 0.084)

-0.033 (-0.148, 0.082)

-0.034 (-0.150, 0.083)

-0.036 (-0.153, 0.081)

-0.093 (-0.206, 0.019)

-0.094 (-0.207, 0.019

sTNFR2

0.071 (-0.044, 0.186)

0.070 (-0.046, 0.185)

0.009 (-0.108, 0.127)

0.008 (-0.110, 0.125)

-0.050 (-0.163, 0.064)

-0.050 (-0.164, 0.064

Total fat %

-0.012 (-0.121, 0.097)

-0.064 (-0.209, 0.080)

0.062 (-0.048, 0.172)

0.070 (-0.077, 0.216)

0.052 (-0.056, 0.159)

0.082 (-0.060, 0.225)

Soft tissue fat %

-0.010 (-0.119, 0.099)

-0.061 (-0.205, 0.083)

0.061 (-0.050, 0.171)

0.067 (-0.079, 0.213)

0.051 (-0.057, 0.158)

0.080 (-0.062, 0.222)

Total fat mass

0.007 (-0.102, 0.115)

-0.049 (-0.214, 0.115)

0.045 (-0.065, 0.155)

0.046 (-0.121, 0.213)

0.038 (-0.069, 0.145)

0.074 (-0.088, 0.237)

Total lean mass

0.043 (-0.064, 0.150)

0.033 (-0.096, 0.161)

-0.019 (-0.127, 0.090)

-0.054 (-0.184, 0.077)

-0.038 (-0.144, 0.067)

-0.061 (-0.188, 0.066)

-0.002 (-0.107, 0.104)

-0.013 (-0.123, 0.097)

0.052 (-0.055, 0.160)

0.047 (-0.065, 0.159)

0.046 (-0.058, 0.151)

0.048 (-0.061, 0.157)

Blood pressure

Cytokines at 16/17 yrs

DEXA

Metabolic syndrome
HOMA
†

hsCRP>10 are excluded (n=10); effects significant at 0.05 level are shown in bold.
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Table 4. Associations between serum testicular hormones and gonadotrophins and metabolic parameters at 20/21 years of age summarised using standardized beta coefficients and their
95% confidence intervals (CI). All beta coefficients were adjusted for age at 20 years of age, history of cryptorchidism and varicocele were made in all analyses (β1) and separate coefficients
are shown with additional adjustment for BMI at 20 years of age (β2). Unless otherwise specified, data were collected at 20/21 years of age.

Biochemistry

Testosterone
β1 (95% CI)
β2 (95% CI)

Inh B
β1 (95% CI)

LH

FSH

β2 (95% CI)

β1 (95% CI)

β2 (95% CI)

β1 (95% CI)

β2 (95% CI)
0.006 (-0.076, 0.087)

Glucose

-0.038 (-0.119, 0.043)

0.002 (-0.077, 0.081)

-0.049 (-0.129, 0.032)

-0.014 (-0.093, 0.065)

-0.018 (-0.098, 0.063)

-0.009 (-0.090, 0.072)

0.003 (-0.077, 0.084)

Triglycerides

-0.128 (-0.209, -0.048)

-0.068 (-0.148, 0.012)

-0.151 (-0.231, -0.072)*

-0.101 (-0.181, -0.021)

0.036 (-0.045, 0.116)

0.053 (-0.030, 0.135)

0.033 (-0.047, 0.114)

0.039 (-0.044, 0.121)

HDL cholesterol

0.201 (0.122, 0.281) *

0.132 (0.051, 0.213) *

0.095 (0.015, 0.175)

0.027 (-0.054, 0.109)

-0.007 (-0.087, 0.073)

-0.027 (-0.111, 0.057)

-0.024 (-0.104, 0.056)

-0.031 (-0.115, 0.053)
-0.018 (-0.101, 0.065)

LDL cholesterol

-0.025 (-0.106, 0.057)

0.038 (-0.042, 0.119)

-0.055 (-0.136, 0.026)

-0.002 (-0.083, 0.078)

-0.057 (-0.138, 0.024)

-0.046 (-0.129, 0.037)

-0.020 (-0.101, 0.061)

Iron

0.173 (0.092, 0.253) *

0.166 (0.089, 0.243) *

0.014 (-0.067, 0.094)

0.008 (-0.071, 0.086)

-0.045 (-0.126, 0.036)

-0.047 (-0.127, 0.034)

-0.056 (-0.136, 0.025)

-0.056 (0.137, 0.025)

Transferrin

-0.011 (-0.092, 0.070)

0.021 (-0.058, 0.099)

0.014 (-0.066, 0.095)

0.042 (-0.036, 0.121)

-0.031 (-0.111, 0.049)

-0.024 (-0.105, 0.057)

-0.035 (-0.116, 0.045)

-0.034 (-0.115, 0.047)

Transferrin saturation %

0.167 (0.086, 0.247) *
-0.095 (-0.176, -0.013)

0.149 (0.071, 0.227) *

0.012 (-0.069, 0.093)

-0.004 (-0.083, 0.075)

-0.032 (-0.113, 0.049)

-0.036 (-0.118, 0.045)

-0.039 (-0.120, 0.042)

-0.040 (-0.121, 0.041)

Ferritin

-0.048 (-0.128, 0.032)

-0.011 (-0.093, 0.070)

0.031 (-0.049, 0.111)

-0.030 (-0.111, 0.051)

-0.020 (-0.103, 0.062)

-0.025 (-0.106, 0.056)

-0.023 (-0.106, 0.059)

Insulin

-0.241 (-0.320, -0.162)*

-0.211(-0.289, -0.132)*

-0.155(-0.236, -0.074)*

-0.012 (-0.093, 0.069)

0.005 (-0.079, 0.090)

0.072 (-0.009, 0.152)

0.083 (-0.002, 0.167)

hsCRP†

-0.249 (-0.329, -0.169)*

-0.177 (-0.258, -0.097)*
-0.187 (-0.268, -0.106)*

-0.024 (-0.106, 0.058)

0.046 (-0.037, 0.129)

-0.073 (-0.155, 0.008)

-0.061 (-0.146, 0.024)

-0.123 (-0.204, -0.042)

-0.129 (-0.214, -0.045)

ALT

-0.116 (-0.197, -0.035)

-0.045 (-0.127, 0.036)

-0.126 (-0.206, -0.045)

-0.067 (-0.148, 0.015)

-0.016 (-0.097, 0.065)

-0.0001 (-0.084, 0.084)

-0.004 (-0.085, 0.077)

-0.001 (-0.085, 0.084)

AST

-0.155 (-0.236, -0.074)

-0.076 (-0.159, 0.008)

-0.149 (-0.230, -0.068)

-0.083 (-0.166, 0.001)

-0.017 (-0.099, 0.065)

0.002 (-0.084, 0.088)

0.038 (-0.044, 0.120)

0.047 (-0.039, 0.133)

GGT

-0.013 (-0.094, 0.068)

0.007 (-0.071, 0.085)

-0.006 (-0.087, 0.074)

0.011 (-0.067, 0.090)

-0.024 (-0.104, 0.057)

-0.028 (-0.135, 0.078)

-0.056 (-0.136, 0.024)

-0.055 (-0.136, 0.025)

Blood pressure
Systolic

-0.084 (-0.165, -0.004)

0.012 (-0.071, 0.095)

-0.129 (-0.208, -0.049)

-0.053 (-0.136, 0.030)

0.002 (-0.079, 0.082)

0.026 (-0.060, 0.111)

0.037 (-0.043, 0.118)

0.048 (-0.038, 0.134)

Diastolic

-0.086 (-0.167, -0.004)

-0.047 (-0.127, 0.032)

-0.075 (-0.156, 0.006)

-0.042 (-0.122, 0.037)

0.050 (-0.032, 0.131)

0.059 (-0.022, 0.141)

0.062 (-0.019, 0.143)

0.065 (-0.017, 0.147)

IL18

-0.020 (-0.112, 0.072)

-0.033 (-0.121, 0.056)

0.020 (-0.071, 0.111)

0.009 (-0.079, 0.098)

0.066 (-0.025, 0.157)

0.063 (-0.028, 0.154)

-0.012 (-0.104, 0.079)

-0.013 (-0.104, 0.978)

sTNFR1

-0.027 (-0.119, 0.064)

-0.010 (-0.099, 0.078)

-0.128 (-0.218, -0.038)

-0.114 (-0.202, -0.026)

0.108 (0.018, 0.198)

0.112 (0.022, 0.202)

0.153 (0.063, 0.242)*

0.154 (0.064, 0.244)*

sTNFR2

-0.004 (-0.095, 0.088)

0.011 (-0.078, 0.099)

-0.011 (-0.102, 0.079)

-0.001 (-0.087, 0.090)

0.039 (-0.051, 0.130)

0.043 (-0.048, 0.134)

0.037 (-0.054, 0.128)

0.038 (-0.053, 0.129)

Total fat %

-0.243 (-0.327, -0.159)*

-0.105 (-0.214, 0.005)

-0.137 (-0.222, -0.052)

0.036 (-0.074, 0.146)

-0.120 (-0.205, -0.035)

-0.139 (-0.252, -0.027)

-0.076 (-0.161, 0.010)

-0.115 (-0.228, -0.002)

Soft tissue fat %

-0.241(-0.325, -0.157)*

-0.103 (-0.212, 0.006)

-0.139 (-0.224, -0.054)

0.031 (-0.079, 0.140)

-0.121 (-0.206, -0.036)

-0.140 (-0.252, -0.028)

-0.074 (-0.159, 0.012)

-0.111 (-0.223, 0.001)

Total fat mass

-0.271 (-0.354, -0.188)*

-0.143 (-0.268, -0.019)

-0.175 (-0.259, -0.091)*

0.010 (-0.114, 0.135)

-0.112 (-0.197, -0.027)

-0.150 (-0.277, -0.022)

-0.058 (-0.143, 0.028)

-0.106 (-0.234, 0.022)

-0.038 (-0.122, 0.047)

0.167 (0.070, 0.265)*

-0.139 (-0.222, -0.055)*

-0.009 (-0.108, 0.089)

0.052 (-0.032, 0.136)

0.124 (0.023, 0.224)

0.086 (0.002, 0.170)

0.136 (0.036, 0.237)

-0.237 (-0.341, -0.133)*

-0.172 (-0.278, -0.066)

-0.203 (-0.282, -0.124)*

-0.149(-0.230, -0.068)*

-0.016 (-0.097, 0.065)

0.001 (-0.083, 0.085)

0.069 (-0.011, 0.150)

0.080 (-0.004, 0.164)

Cytokines at 16/17 yrs

DEXA

Total lean mass
Metabolic syndrome
HOMA
†

hsCRP>10 are excluded (n=10); effects significant at 0.05 level are shown in bold. *p = or <0.001

7
Table 5. Comparison of testicular volume, semen parameters and serum hormones by metabolic clusters, all
assessments made at 20 years of age in the top part of the table, and metabolic cluster analysis and associations
at 17 years of age are listed in the lower part of the table. Data is represented as Median (IQR, R) and Mean (SD)
as appropriate.
Cluster parameters at 20
years of age
Systolic blood pressure
(mm/Hg)
Insulin (μu/ml)
Triglycerides (mmol/l)
Waist circumference (cm)

N

High risk at 20 years of age
[Mean (SD)]

NLow

Low risk at 20 years of age
[Mean (SD)]

p-value

43

130.8 (10.6)

342

121.8 (12.2)

<0.001

43
43
43

14.2 (12.8)
1.8 (1.1)
100.2 (12.9)

342
342
342

3.2 (2.2)
1.0 (0.4)
80.2 (7.6)

<0.001
<0.001
<0.001

0.574

Hig
h

Metabolic cluster at 20 years of age
Testicular function
assessment at 20 years
Testicular volume (ml)
Semen parameters
Volume (ml)
Total sperm output (M)
Sperm concentration
(M/mL)
SCSA (%)
Morphology (N, %)
Motility (a + b, %)
Serum hormones
Testosterone (ng/ml)
LH (IU/l)
FSH (IU/l)
InhB (pg/ml)

42

High risk at 20 years of age
[Median (IQR, R)]
14.7 (12.3-16.9, 9.0-23.8)

325

Low risk at 20 years of age
[Median (IQR, R)]
15.2 (13.0-17.4, 7.6-28.4)

34
34
34

2.7 (1.9-4.0, 0.9-7.2)
115.3 (51.0-194.0, 0.0-551.8)
42.5 (19.4-70.5, 0-142)

303
303
303

2.8 (1.9-3.7, 0.1-11.0)
113.4 (50.6-207.0, 0.0-927.5)
46 (23-73, 0-220)

0.979
0.738
0.663

32
32
33

2.5 (1.5-4.7, 0.6-10.8)
5.5 (3.6-9.0, 3-17)
58.0 (43.5-70.5, 19-86)

298
294
300

3.1 (1.9-5.2, 0.2-30.0)
5 (3-7, 0-18)
58 (44-67, 1-88)

0.106
0.144
0.773

75
76
76
76

3.6 (3.0-4.0, 1.1-6.5)
6.7 (7.6-12.8, 5.2-19.3)
4.4 (2.9-6.8, 0.8-25.8)
167.9 (132.1-217.0, 28.9-389.3)

522
522
522
523

4.8 (3.8-5.9, 1.3-10.3)
10.5 (8.3-13.1, 2.3-28.4)
4.3 (3.0-6.1, 0.6-39.5)
223.7 (180.6-272.9, 4.5-543.9)

<0.001
0.097
0.492
<0.001

0.215

Metabolic cluster at 17 years of age
Testicular function
assessment at 20 years
Testicular volume (ml)
Semen parameters
Volume (ml)
Total sperm output (M)
Sperm concentration
(M/mL)
SCSA (%)
Morphology (N, %)
Motility (a + b, %)
Serum hormones
Testosterone (ng/ml)
LH (IU/l)
FSH (IU/l)
InhB (pg/ml)

39

High risk at 16/17 yrs of age
[Median (IQR, R)]
15.6 (13.3-17.5, 10.1-23.2)

249

Low risk at 16/17 yrs of age
[Median (IQR, R)]
14.7 (12.6-17.1, 8.0-28.4)

37
37
37

2.5 (1.6-3.6, 0.3-11.0)
110.7 (52.2-288.9, 0.0-592.2)
50 (26.5-88.5, 0-220)

227
227
227

2.8 (2.0-3.6, 0.7-7.5)
122.2 (56.0-217.6, 0.0-927.5)
47 (23-71, 0-210)

0.347
0.711
0.280

35
35
36

3.6 (1.8-6.5, 0.7-30)
5.0 (3.0-7.0, 0.5-17)
51.0 (38.5-65.8, 7.0-88.0)

222
219
224

3.3 (1.9-5.5, 0.2-19.0)
4.5 (3.0-7.0, 0.5-18.0)
59.0 (43.3-68.0, 7.0-88.0)

0.416
0.782
0.170

67
68
68
68

4.0 (3.2-4.9, 1.6-7.2)
10.1 (7.8-13.9, 5.4-19.8)
4.4 (3.4-6.8, 1.1-14.3)
193.2 (144.8-226.5, 48.7-389.3)

356
357
357
357

4.9 (3.6-6.0, 1.8-9.9)
10.6 (8.6-13.2, 4.3-28.4)
4.3 (3.0-6.2, 0.8-39.5)
221.9 (180.3-269.0, 56.7543.9)

<0.001
0.425
0.285
<0.001

8
Table 6. Comparison of testicular volume, semen parameters and serum testicular hormones and gonadotrophins
by HOMA-IR, all assessments made at 20 years of age. Data is represented as Median (IQR, R).
Testicular function
assessment
Testicular volume (ml)
Sperm parameters
Semen volume (ml)
Total sperm output (M)
Sperm concentration (M/ml)
SCSA (%)
Sperm morphology (N, %)
Sperm motility (a + b, %)
Serum hormone concentrations
Testosterone (ng/ml)
LH (IU/l)
FSH (IU/l)
InhB (pg/ml)

NIR

IR (HOMA>4)

NNormal

Normal (HOMA≤4)

p-value

14

12.8 (11.1-14.7, 10.0-16.9)

359

15.2 (13.0-17.4, 7.6-28.4)

0.010

13
13

2.6 (1.5-3.6, 0.9-4.2)
136.8 (81.0-253.9, 0.0383.4)
64.0 (30.0-88.5, 0-160)
2.8 (1.5-5.4, 1.4-10.8)
5.5 (3.3-10.0, 3-17)
63 (47.3-75.8, 26-79)

326
326

2.8 (1.9-3.8, 0.1-11.0)
110.6 (50.6-206.7, 0.0927.5)
44.5 (22.0-70.3, 0-220)
3.1 (1.8-5.2, 0.2-30.0)
5 (3-7, 0-18)
58 (43-67, 1-88)

0.320
0.459

3.2 (2.6-4.0, 1.1-5.3)
10.6 (8.2-13.3, 6.3-17.1)
6.1 (3.4-7.9, 1.1-14.3)
172.4 (130.0-213.4, 54.8389.3)

583
584
584
585

4.6 (3.7-5.9, 1.3-10.3)
10.5 (8.3-13.0, 2.3-28.4)
4.3 (3.0-6.1, 0.6-39.5)
217.8 (174.0-267.6, 4.5543.9)

<0.001
0.903
0.046
0.001

13
12
12
12
24
24
24
24

326
320
316
323

HOMA = homeostasis model assessment insulin (Fasting insulin [μu/ml] × Fasting glucose [mM]/22.5).

0.293
0.654
0.402
0.330

